Skip to content

The Effects of Weight Reduction in IgA Nephropathy

The Effects of Weight Reduction in Chronic Proteinuric IgA Nephropathy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01773382
Acronym
WeightPro
Enrollment
30
Registered
2013-01-23
Start date
2012-10-31
Completion date
2013-04-30
Last updated
2013-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Proteinuria

Brief summary

The study aims to explore the non-pharmacological treatment of IgA nephropathy by weight reduction. The investigators hypothesized that benefits of weight loss may reduce proteinuria.

Detailed description

This is a prospective randomized study in adult IgA nephropathy. The investigators enrolled 30 patients who have proteinuria exceeds 1 g per day with biopsy proven IgA nephropathy. The experimental arm recieves the non-pharmacological treatment, weight reduction protocol. All patients in this arm must be reduce their body weight in 3-5 % from baseline as protocol. Another arm is control group which recieves standard treatment of IgA nephropathy including ACEIs/ARBs for blood pressure control (target \< 130/80 mmHg). The primary outcome is proteinuria level. The secondary outcome is cytokines and inflammatory markers level including interleukin-6, resistin, adiponectin, leptin and monocyte chemoattractant protein-1.

Interventions

BEHAVIORALweight reduction

1. Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal) 2. Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks. 3. Daily body weight measurement. 4. Record food diary

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Biopsy-proven IgA nephropathy * body mass index more than 23 Kg/m2 * 24 hours urine protein more than 1 g * estimated GFR more than 20 ml/min

Exclusion criteria

* pregnancy and lactation * rapidly renal function decline * crescent formation in renal biopsy more than 10%

Design outcomes

Primary

MeasureTime frameDescription
Percentage change of 24-hour proteinuria6 monthsThe investigators measure amount of 24-hour proteinuria at randomization peroid ( as baseline), first, third and sixth month. Then, investigators calculate the percentage reduction of proteinuria at different time points.

Secondary

MeasureTime frameDescription
plasma concentration of IL-6, adiponectin, resistin, leptin, MCP-16 monthsThe investigators measure amount of plasma concentration of IL-6, adiponectin, resistin, leptin, MCP-1 at randomization peroid ( as baseline) and sixth month. Then, investigators calculate the percentage reduction of these cytokines in 6 months peroid.

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026